MIB-1 counting methods in meningiomas and agreement among pathologists

Analytical and Quantitative Cytology and Histology

Volumn 30, Issue 1, 2008, Pages 47-52

  Rezanko, Turkan ^a,b   Akkalp, Asli Kahraman ^a   Tunakan, Mine ^a   Sari, Aysegul Akder ^a  

^a ATATURK TRAINING AND RESEARCH HOSPITAL   (Turkey)

^b Mimkent Esentepe Uckuyular   (Turkey)

Author keywords

Counting method; Meningioma; MIB 1

Indexed keywords

KI 67 ANTIGEN; MONOCLONAL ANTIBODY KI 67;

ARTICLE; CANCER GRADING; CELL COUNT; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; LABELING INDEX; MAJOR CLINICAL STUDY; MENINGIOMA; OBSERVER VARIATION; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTIBODIES, ANTINUCLEAR; ANTIBODIES, MONOCLONAL; HUMANS; KI-67 ANTIGEN; MENINGEAL NEOPLASMS; MENINGIOMA; NEOPLASM RECURRENCE, LOCAL; OBSERVER VARIATION; PROGNOSIS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 39749188362     PISSN: 08846812     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Jaaskelainen J: Seemingly complete removal of histologically benign intracranial meningioma: Late recurrence rate and factors predicting recurrence in 657 patients: A multivariate analysis. Surg Neurol 1986;5:461-469
2. Brown DC, Gatter KC: Ki-67 protein: The immaculate deception? Histopathology 2002;40:2-11
3. Kolles H, Niedermayer I, Schmitt C, Henn W, Feld R, Steudel WI, Zang KD: Triple approach for diagnosis and grading of meningiomas: Histology, morphometry of Ki-67/Feulgen stainings, and cytogenetics. W Acta Neurochir (Wien) 1995;137:174-181
4. Nakasu S, Li DH, Okabe H, Nakajima M, Matsuda M: Significance of MIB-1 staining indices in meningiomas: Comparison of two counting methods. Am J Surg Pathol 2001;25:472-478
5. Ozen O, Demirhan B, Altinors N: Correlation between histological grade and MIB-1 and p53 immunoreactivity in meningiomas. Clin Neuropathol 2005;24:219-224
6. Karamitopoulou E, Perentes E, Tolnay M, Probst A: Prognostic significance of MIB-1, p53 and bcl-2 immunoreactivity in meningiomas. Hum Pathol 1998;291:140-145
7. Lanzafame S, Torrisi A, Barbagallo G, Emmanuele C, Alberio N, Albanese V: Correlation between histological grade, MIB-1, p53, and recurrence in 69 completely resected primary intracranial meningiomas with a 6 year mean follow-up. Pathol Res Pract 2000;196:483-438
8. Torp SH, Lindboe CF, Gronberg BH, Lydersen S, Sundstrom S: Prognostic significance of Ki-67/MIB-1 proliferation index in meningiomas. Clin Neuropathol 2005;24:170-174
9. Perry A, Stafford SL, Scheithauer BW, Suman VJ, Lohse CM: The prognostic significance of MIB-1, p53, and DNA flow cytometry in completely resected primary meningiomas. Cancer 1998;82:2262-2269
10. Tyagi A, Chakrabarty A, Franks A: MIB1 proliferation index in meningiomas: Does it predict recurrence? A clinicopathological study. Br J Neurosurg 2004;18:357-361
11. Schiffer D, Ghimenti C, Fiano V: Absence of histological signs of tumor progression in recurrences of completely resected meningiomas. J Neurooncol 2005;73:125-130
12. Roser F, Samii M, Ostertag H, Bellinzona M: The Ki-67 proliferating antigen in meningiomas: Experience in 600 cases. Acta Neurochir (Wien) 2004;146:37-44
13. Goldblum JR, Shannon R, Kaldjian EP, Thiny M, Davenport R, Thompson N, Lloyd RV: Immunohistochemical assessment of proliferative activity in adrenocortical neoplasms. Mod Pathol 1993;6:663-668
14. Grzybicki DM, Liu Y, Moore SA, Brown HG, Silverman JF, D'Amico F, Raab SS: Interobserver variability associated with the MIB-1 labeling index: High levels suggest limited prognostic usefulness for patients with primary brain tumors. Cancer 2001;92:2720-2726
15. Abramovich CM, Prayson RA: MIB-1 labeling indices in benign, aggressive and malignant meningiomas: A study of 90 tumors. Human Pathol 1998;29:1422-1427
16. Hsu DW, Efird JT, Healey-Whyte ET: MIB-1 (Ki-67) index and transforming growth factor-alpha (TGF-α) immunreactivity are significant prognostic predictors for meningiomas. Neuropathol Appl Neurol 1998;24:441-452
17. Moller ML, Braendstrup O: No prediction of recurrence of meningiomas by PCNA and Ki-67 immunohistochemistry. J Neurooncol 1997;34:241-246
18. Abramovich CM, Prayson RA: Histopathologic features and MIB-1 labeling indices in recurrent and nonrecurrent meningiomas. Arch Pathol Lab Med 1999;123:793-800
19. Matsuno A, Fujimaki T, Sasaki T, Nagashima T, Ide T, Asai A, Matsuura R, Utsunomiya H, Kirino T: Clinical and histopathological analysis of proliferative potentials of recurrent and nonrecurrent meningiomas. Acta Neuropathol 1996;91:504-510
20. Louis DN, Scheithauer BW, Budka H, Deimling A, Kepes JJ: Meningiomas. In Pathology and Genetics Tumors of the Nervous System. Edited by P Kleihues, WK Cavenee. Lyon, IARC Press, 2000, pp 179-184
21. Mengel M, Wasielewski R, Wiese B, Rüdiger T, Müllerhermelink HK, Kreipe H: Inter-laboratory and inter-observer reproducibility of immunohistochemical assessment of the Ki-67 labelling index in a large multi-centre trial. J Pathol 2002;198:292-299
22. Siegers HP, Zuber P, Hamou MF, van Melle GD, Tribolet N: The implications of the heterogeneous distribution of Ki-67 labelled cells in meningiomas. Br J Neurosurg 1989;3:101-107
23. Hsu CY, Ho DM, Yang CF, Chiang H: Interobserver reproducibility of MIB-1 labeling index in astrocytic tumors using different counting methods. Mod Pathol 2003;16:951-957